TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33140125

Group type: EXPERIMENTAL
Intervention: Selenised yeast supplementation at 100, 200, and 300 μg Se/day for 6 months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Selenised yeast supplementation at doses over 100 μg Se/day for 5 years
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 33982100

Group type: EXPERIMENTAL
Intervention: Superhero television show
Number of subjects: 59

Group type: COMPARATOR
Intervention: Comparable nonsuperhero show
Number of subjects: 59
Study: 35437837

Group type: EXPERIMENTAL
Intervention: Eliapixant (10-800 mg)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Eliapixant with high-fat breakfast
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Eliapixant with low-fat breakfast
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Eliapixant with itraconazole
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Eliapixant
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study: 35713888

Group type: EXPERIMENTAL
Intervention: Baroreflex activation therapy (BAT) + guideline-directed medical therapy (GDMT)
Number of subjects: 554

Group type: COMPARATOR
Intervention: Guideline-directed medical therapy (GDMT) alone
Number of subjects: 554
Study: 32061506

Group type: EXPERIMENTAL
Intervention: Selexipag
Number of subjects: 1156

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1156
Study: 35916340

Group type: EXPERIMENTAL
Intervention: Varenicline treatment
Number of subjects: 15
Study: 33678400

Group type: EXPERIMENTAL
Intervention: Brush Day & Night (BDN) programme
Number of subjects: 2771
Study: 32469393

Group type: EXPERIMENTAL
Intervention: Ex + MFMD (n=123)
Number of subjects: 244

Group type: COMPARATOR
Intervention: Ex + placebo (n=121)
Number of subjects: 244
Study: 33579160

Group type: EXPERIMENTAL
Intervention: ICCR (MyoRing, Dioptex GmbH, Austria)
Number of subjects: 32

Group type: COMPARATOR
Intervention: ICRS (Keraring, Mediphacos, Brazil)
Number of subjects: 32
Study: 33687796

Group type: EXPERIMENTAL
Intervention: Er:YAG laser
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Titanium brush
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Carbon fiber curet
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control
Number of subjects: 8
Study: 32748345

Group type: EXPERIMENTAL
Intervention: Advanced notification phone call
Number of subjects: 3240

Group type: COMPARATOR
Intervention: No phone call
Number of subjects: 3240

Group type: COMPARATOR
Intervention: Voicemail or no voicemail
Number of subjects: 3240

Group type: COMPARATOR
Intervention: No voicemail
Number of subjects: 3240
Study: 35949044

Group type: EXPERIMENTAL
Intervention: Long-acting injectable cabotegravir (CAB-LA)
Number of subjects: 133
Study: 33709543

Group type: EXPERIMENTAL
Intervention: AMC-trained group (abacus training for 2 hours per week for 5 years)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: AMC-trained group
Number of subjects: 63

Group type: COMPARATOR
Intervention: Nontrained group
Number of subjects: 63
Study: 35123401

Group type: EXPERIMENTAL
Intervention: Basmisanil 120 mg BID
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Basmisanil 240 mg BID
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Basmisanil (both doses)
Number of subjects: 0
Study: 33381933

Group type: EXPERIMENTAL
Intervention: DW‐7202 (capsule type)
Number of subjects: 0

Group type: COMPARATOR
Intervention: AST‐120 (granule type)
Number of subjects: 0
Study: 32069068

Group type: EXPERIMENTAL
Intervention: Driving pressure-limited strategy (ventilated with volume-controlled or pressure-support modes, tidal volume titrated to 4-8 ml/kg of predicted body weight, aiming for a driving pressure of 10 cm H2O or the lowest possible)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Driving pressure-limited strategy
Number of subjects: 31

Group type: COMPARATOR
Intervention: Conventional lung-protective ventilation strategy (ARDSNet protocol, tidal volume of 6 ml/kg PBW, adjustable to 4 ml/kg PBW if plateau pressure >30 cm H2O)
Number of subjects: 31
Study: 36238498

Group type: EXPERIMENTAL
Intervention: Hospital-community-family integrated management
Number of subjects: 60
Study: 33902468

Group type: EXPERIMENTAL
Intervention: Training group (Group A)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Self-training group (Group B)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Control group (Group C)
Number of subjects: 154
Study: 32890016

Group type: EXPERIMENTAL
Intervention: High-flow nasal oxygen (HFNO) at 10 l/min before sedation and 50 l/min during the procedure
Number of subjects: 59

Group type: COMPARATOR
Intervention: Conventional oxygen face mask at 10 l/min during the procedure
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: High-flow nasal oxygen (HFNO)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Conventional oxygen face mask
Number of subjects: 59
Study: 34775437

Group type: EXPERIMENTAL
Intervention: Robot-assisted training
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control group (no training program)
Number of subjects: 11
Study: 35134988

Group type: COMPARATOR
Intervention: Standard treatment (brief counseling)
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Intensive treatment (sustained counseling plus smoking cessation medication)
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: E‐cigarette use
Number of subjects: 303
Study: 33098644

Group type: EXPERIMENTAL
Intervention: AZD4017
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 32358379

Group type: EXPERIMENTAL
Intervention: Acupuncture combined therapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Chinese patent medicine
Number of subjects: 60
Study: 35272320

Group type: EXPERIMENTAL
Intervention: Concomitant midurethral sling
Number of subjects: 183

Group type: COMPARATOR
Intervention: No concomitant midurethral sling
Number of subjects: 183
Study: 35007358

Group type: EXPERIMENTAL
Intervention: Cold Atmospheric Plasma (CAP)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 32715917

Group type: EXPERIMENTAL
Intervention: Bevacizumab treatment with urine protein monitoring every other treatment
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Bevacizumab treatment with urine protein monitoring every third treatment
Number of subjects: 55
Study: 32667903

Group type: EXPERIMENTAL
Intervention: Conditioned Pain Modulation (CPM) response - limited
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Conditioned Pain Modulation (CPM) response - normal
Number of subjects: 63
Study: 35617872

Group type: EXPERIMENTAL
Intervention: Typhoid vaccine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 34432113

Group type: EXPERIMENTAL
Intervention: Percutaneous Coronary Intervention (PCI)
Number of subjects: 1771

Group type: COMPARATOR
Intervention: Coronary Artery Bypass Grafting (CABG)
Number of subjects: 1771

Group type: COMPARATOR
Intervention: Patients without CVD
Number of subjects: 1771

Group type: EXPERIMENTAL
Intervention: Patients with CVD in ≥ 2 territories
Number of subjects: 1771
Study: 33248880

Group type: EXPERIMENTAL
Intervention: Oral immunotherapy (OIT) with rush immunotherapy for 2 weeks, followed by a gradual increase of cow's milk volume to 100 mL for 1 year.
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Oral immunotherapy (OIT)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (complete elimination of cow's milk for 1 year)
Number of subjects: 28
Study: 32274677

Group type: EXPERIMENTAL
Intervention: Formula-feeding
Number of subjects: 0

Group type: COMPARATOR
Intervention: Breastfeeding plus extended infant zidovudine prophylaxis
Number of subjects: 0
Study: 33847224

Group type: EXPERIMENTAL
Intervention: Cervical exams every 1–2 h in active labor
Number of subjects: 491

Group type: EXPERIMENTAL
Intervention: Cervical exams every 2–4 h in latent labor
Number of subjects: 491

Group type: EXPERIMENTAL
Intervention: Misoprostol utilization not continued beyond 6 doses or 24 h
Number of subjects: 491
Study: 34098331

Group type: EXPERIMENTAL
Intervention: 10% lidocaine spray
Number of subjects: 144

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study: 35580191

Group type: EXPERIMENTAL
Intervention: Rivaroxaban (10mg once daily for 3 weeks starting 7±2 days after surgery)
Number of subjects: 582
Study: 33185002

Group type: EXPERIMENTAL
Intervention: linagliptin 5 mg
Number of subjects: 6033

Group type: COMPARATOR
Intervention: glimepiride 1 to 4 mg
Number of subjects: 6033
Study: 34711771

Group type: EXPERIMENTAL
Intervention: Resistance priming
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (rest)
Number of subjects: 20
Study: 33119538

Group type: EXPERIMENTAL
Intervention: Intensity of information source use for COVID-19
Number of subjects: 418

Group type: EXPERIMENTAL
Intervention: Intensity of social media use for COVID-19
Number of subjects: 418

Group type: EXPERIMENTAL
Intervention: Higher COVID-19 threat appraisal
Number of subjects: 418

Group type: EXPERIMENTAL
Intervention: Higher COVID-19 coping appraisal
Number of subjects: 418

Group type: EXPERIMENTAL
Intervention: Higher intensity of COVID-19 knowledge
Number of subjects: 418
Study: 37019385

Group type: EXPERIMENTAL
Intervention: ivarmacitinib 2 mg once daily
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: ivarmacitinib 4 mg once daily
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: ivarmacitinib 8 mg once daily
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study: 32917556

Group type: EXPERIMENTAL
Intervention: GFF MDI (18/9.6 μg)
Number of subjects: 150
Study: 32410694

Group type: EXPERIMENTAL
Intervention: Atabecestat 10 mg once daily
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Atabecestat 50 mg once daily (later reduced to 25 mg)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Atabecestat (various dosages)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 114
Study: 35099555

Group type: EXPERIMENTAL
Intervention: Darvadstrocel
Number of subjects: 89

Group type: COMPARATOR
Intervention: Control
Number of subjects: 89
Study: 32852428

Group type: EXPERIMENTAL
Intervention: 595-nm Pulsed Dye Laser treatment (fluence 7.5 J/cm2, 3-ms pulse duration, no dynamic cooling, 10-mm spot size, 10% overlap between pulses, 2 stacked pulses)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sham/control treatment
Number of subjects: 24
Study: 35815882

Group type: EXPERIMENTAL
Intervention: Post-discharge mobile app
Number of subjects: 282

Group type: COMPARATOR
Intervention: Usual postoperative care
Number of subjects: 282
Study: 33820208

Group type: EXPERIMENTAL
Intervention: EGN model for predicting the impact of fiber nonlinearity on optical coherent transmission systems at zero or near-zero dispersion.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Closed-form EGN-model approximation capable of handling high, low, and near-zero or zero dispersion fibers.
Number of subjects: 0
Study: 35260948

Group type: EXPERIMENTAL
Intervention: Waterpipe with pictorial health warning label (PHWL)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Waterpipe with no pictorial health warning label (no-PHWL)
Number of subjects: 60
Study: 34452786

Group type: EXPERIMENTAL
Intervention: Microosteoperforations (MOPs) procedure under local anesthesia using a Propel device
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (conventional treatment)
Number of subjects: 30
Study: 33284337

Group type: EXPERIMENTAL
Intervention: Financial toxicity (FT)
Number of subjects: 536

Group type: EXPERIMENTAL
Intervention: Conversations about costs
Number of subjects: 536
Study: 33297830

Group type: EXPERIMENTAL
Intervention: OTC information only
Number of subjects: 778

Group type: EXPERIMENTAL
Intervention: OTC information plus POP information
Number of subjects: 778
Study: 32144909

Group type: EXPERIMENTAL
Intervention: Low-frequency electrical acupoint stimulation (LEAS)
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Fast track surgery (FTS)
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: FTS + LEAS
Number of subjects: 177

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: LEAS
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: FTS
Number of subjects: 177
Study: 34813821

Group type: EXPERIMENTAL
Intervention: HRV-guided training (HRV-G)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Traditional training (TRAD-G)
Number of subjects: 12
Study: 33511688

Group type: EXPERIMENTAL
Intervention: Staphylococcus hominis applied on half-side of cheek for eight times in 1 month
Number of subjects: 293

Group type: COMPARATOR
Intervention: Placebo side
Number of subjects: 293
Study: 32559817

Group type: EXPERIMENTAL
Intervention: Systemic treatment (immune or targeted therapy)
Number of subjects: 2536

Group type: EXPERIMENTAL
Intervention: ECOG PS ≥2 with symptomatic brain metastases
Number of subjects: 2536

Group type: EXPERIMENTAL
Intervention: ECOG PS ≥2 without symptomatic brain metastases
Number of subjects: 2536

Group type: EXPERIMENTAL
Intervention: LDH >500 U/L
Number of subjects: 2536
Study: 35674759

Group type: EXPERIMENTAL
Intervention: Probiotic capsules containing multi-strain at least 1.6×10^9 CFU/g bacteria
Number of subjects: 46
Study: 32665035

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) 300 mg
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Unfractionated heparin (UFH) (low or moderate dose)
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Both ASA and UFH
Number of subjects: 1500

Group type: COMPARATOR
Intervention: Neither ASA nor UFH
Number of subjects: 1500
Study: 35140061

Group type: EXPERIMENTAL
Intervention: App-based education programme for salt reduction
Number of subjects: 592

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 592
Study: 34111130

Group type: EXPERIMENTAL
Intervention: iStent inject trabecular bypass stent (TBS) + cataract surgery (Cat Sx)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cataract surgery (Cat Sx) alone
Number of subjects: 0
Study: 33587543

Group type: EXPERIMENTAL
Intervention: EXOGEN Ultrasound Bone Healing System
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard fracture care
Number of subjects: 0
Study: 32218747

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Psychoeducation Group (MBPEG) program
Number of subjects: 124
Study: 33988772

Group type: EXPERIMENTAL
Intervention: CU‐CNPs
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: CNPs
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: %6 NaOCl
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: %6 NaOCl+%9 editronate (HEBP)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Distilled water (Control)
Number of subjects: 50
Study: 32674675

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 10 mg (R10)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 15 mg (R15)
Number of subjects: 105

Group type: COMPARATOR
Intervention: DAPT (aspirin 75 mg and clopidogrel 75 mg)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 10 mg (R10) and Rivaroxaban 15 mg (R15)
Number of subjects: 105
Study: 36462524

Group type: EXPERIMENTAL
Intervention: N lactamica (105 CFU in 1 mL PBS)
Number of subjects: 31

Group type: COMPARATOR
Intervention: PBS (1 mL PBS)
Number of subjects: 31
Study: 33047696

Group type: EXPERIMENTAL
Intervention: Phase-contrast video microscopy method in addition to conventional method
Number of subjects: 53

Group type: COMPARATOR
Intervention: Conventional method
Number of subjects: 53
Study: 35150215

Group type: EXPERIMENTAL
Intervention: Aquablation
Number of subjects: 181

Group type: COMPARATOR
Intervention: TURP
Number of subjects: 181
Study: 34183490

Group type: EXPERIMENTAL
Intervention: Desvenlafaxine
Number of subjects: 4317

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4317
Study: 33316604

Group type: EXPERIMENTAL
Intervention: Anodal tDCS over left lateral PFC
Number of subjects: 121

Group type: COMPARATOR
Intervention: Control tDCS over temporoparietal cortex
Number of subjects: 121

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 121
Study: 32716349

Group type: EXPERIMENTAL
Intervention: Five commercial EV isolation kits
Number of subjects: 3

Group type: COMPARATOR
Intervention: Ultracentrifugation (UC)
Number of subjects: 3
Study: 32038628

Group type: EXPERIMENTAL
Intervention: Acute dynamic exercise
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nadolol (β1 + β2‐AR antagonist)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bisoprolol (β1‐AR antagonist)
Number of subjects: 0
Study: 34548531

Group type: EXPERIMENTAL
Intervention: Fenofibrate for six weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 33207825

Group type: EXPERIMENTAL
Intervention: Novel method for automatic detection of red lesions (RLs) using proprietary database
Number of subjects: 564

Group type: EXPERIMENTAL
Intervention: Novel method for automatic detection of red lesions (RLs) using public database
Number of subjects: 564

Group type: EXPERIMENTAL
Intervention: Novel method for automatic detection of exudates (EXs) using proprietary database
Number of subjects: 564

Group type: EXPERIMENTAL
Intervention: Novel method for automatic detection of exudates (EXs) using public database
Number of subjects: 564
Study: 34148509

Group type: EXPERIMENTAL
Intervention: Static stretching of ankle plantar flexors for 5 minutes
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control condition (standing for 6 minutes)
Number of subjects: 26
Study: 33720367

Group type: EXPERIMENTAL
Intervention: Endoscopic vein harvesting
Number of subjects: 0

Group type: COMPARATOR
Intervention: Open vein harvesting
Number of subjects: 0
Study: 32610465

Group type: EXPERIMENTAL
Intervention: Probiotics (Lactobacillus Casei Shirota strain 3 × 10^10 CFU)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo drink
Number of subjects: 20
Study: 35676543

Group type: EXPERIMENTAL
Intervention: Conventional training
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Laparoscopic training
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Robotic training
Number of subjects: 66
Study: 34887657

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG) treatment
Number of subjects: 70

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG) treatment (in adherent patients)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Normal saline (control) (in adherent patients)
Number of subjects: 70
Study: 33165116

Group type: EXPERIMENTAL
Intervention: Selegiline hydrochloride
Number of subjects: 0
Study: 35420272

Group type: EXPERIMENTAL
Intervention: LLR algorithm-based model
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Combined radiomics features with clinical features
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: SVM classifier with radial kernel function
Number of subjects: 100
Study: 32991794

Group type: EXPERIMENTAL
Intervention: 25 μg mRNA-1273 vaccine
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 100 μg mRNA-1273 vaccine
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: mRNA-1273 vaccine (both doses)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: mRNA-1273 vaccine
Number of subjects: 40
Study: 36088426

Group type: EXPERIMENTAL
Intervention: Complete macroscopic en bloc resection with adjacent structures
Number of subjects: 0

Group type: COMPARATOR
Intervention: Preoperative radiotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Histology-tailored chemotherapy regimen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Observational studies
Number of subjects: 0
Study: 35427481

Group type: EXPERIMENTAL
Intervention: EV71vac (aluminium phosphate‐adjuvanted inactivated EV71 vaccine), administered as two doses via intramuscular injection 56 days apart, with a third booster dose for children aged 2-23 months on day 366.
Number of subjects: 3061

Group type: COMPARATOR
Intervention: Placebo, administered as two doses via intramuscular injection 56 days apart.
Number of subjects: 3061

Group type: EXPERIMENTAL
Intervention: EV71vac (aluminium phosphate‐adjuvanted inactivated EV71 vaccine)
Number of subjects: 3061
Study: 34578925

Group type: EXPERIMENTAL
Intervention: DASH diet intervention
Number of subjects: 79

Group type: COMPARATOR
Intervention: Control group (no dietary intervention)
Number of subjects: 79
Study: 33057823

Group type: EXPERIMENTAL
Intervention: Single application of Olanedine
Number of subjects: 393

Group type: EXPERIMENTAL
Intervention: Double application of Olanedine
Number of subjects: 393

Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 393
Study: 34581220

Group type: EXPERIMENTAL
Intervention: Slowed down rehabilitation
Number of subjects: 60

Group type: COMPARATOR
Intervention: Traditional rehabilitation
Number of subjects: 60
Study: 33928516

Group type: EXPERIMENTAL
Intervention: Articulatory consciousness training (32 individual sessions over 8 weeks)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control condition (baseline tests)
Number of subjects: 11
Study: 33933433

Group type: EXPERIMENTAL
Intervention: 20-Hz rTMS on individualized inferior parietal lobule (IPL) targets
Number of subjects: 0

Group type: COMPARATOR
Intervention: rTMS of the pre-supplementary motor area (preSMA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Stroop task
Number of subjects: 0
Study: 32115719

Group type: EXPERIMENTAL
Intervention: HIV-1 genotypic characteristics and transmitted drug resistance surveillance
Number of subjects: 224
Study: 34718635

Group type: EXPERIMENTAL
Intervention: 100 g, 200 g, 300 g whole beetroot (BR)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 200 g whole beetroot (BR)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 300 g whole beetroot (BR)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Potassium nitrate (1000 mg)
Number of subjects: 24
Study: 33981951

Group type: EXPERIMENTAL
Intervention: Physical Activity greater than 9 MET hours per week
Number of subjects: 799

Group type: COMPARATOR
Intervention: Physical Activity 0-9 MET hours per week
Number of subjects: 799
Study: 32867508

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 14005
Study: 36469317

Group type: EXPERIMENTAL
Intervention: Patient decision aid targeted to age and sex
Number of subjects: 424
Study: 33781913

Group type: EXPERIMENTAL
Intervention: ChAd63-KH vaccine (1 × 10^10 viral particles for adults, 7.5 × 10^10 viral particles for adults and adolescents)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: ChAd63-KH vaccine
Number of subjects: 24

Group type: COMPARATOR
Intervention: AmBisome
Number of subjects: 24
Study: 36409754

Group type: EXPERIMENTAL
Intervention: HIV recency assay and viral load quantification using Asanté HIV‐1 Rapid Recency Assay and Roche Cobas System
Number of subjects: 184